Rasio utang jangka cendhak marang ekuitas: NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals (NRBO) is expanding its portfolio of treatments for MASH and metabolic disorders to secure future dominance in neuropharmaceuticals, a trend reflected in the chart with a market price currently at 0.01. However, global conflicts and sanctions are hindering international trials and the supply of biomaterials. Development stability is maintained through the creation of strategic reserves of chemical components to eliminate logistics disruptions.

Striving for FDA approval while remaining dependent on a Korean majority shareholder, NeuroBo Pharmaceuticals (NRBO) utilizes borrowed funds to finance clinical stages, where the ratio of short-term liabilities (up to one year) to equity reflects the degree of financial risk and expansion aggressiveness, allowing investors to assess the company's vulnerability to rising interest rates via a short-term debt-to-equity ratio chart.